Cargando…

SARS-CoV-2 Persistent Viral Shedding in the Context of Hydroxychloroquine-Azithromycin Treatment

SARS-CoV-2 nasopharyngeal shedding contributes to the spread of the COVID-19 epidemic. Among 3271 COVID-19 patients treated at the Hospital University Institute Méditerranée Infection, Marseille, France from 3 March to 27 April 2020, tested at least twice by qRT-PCR, the median SARS-CoV-2 nasopharyn...

Descripción completa

Detalles Bibliográficos
Autores principales:	Drancourt, Michel, Cortaredona, Sébastien, Melenotte, Cléa, Amrane, Sophie, Eldin, Carole, La Scola, Bernard, Parola, Philippe, Million, Matthieu, Lagier, Jean-Christophe, Raoult, Didier, Colson, Philippe
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2021
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8150993/ https://www.ncbi.nlm.nih.gov/pubmed/34065871 http://dx.doi.org/10.3390/v13050890

Ejemplares similares

Outcomes of 2111 COVID-19 Hospitalized Patients Treated with Hydroxychloroquine/Azithromycin and Other Regimens in Marseille, France, 2020: A Monocentric Retrospective Analysis
por: Lagier, Jean-Christophe, et al.
Publicado: (2022)

Asymptomatic hypoxia in COVID-19 is associated with poor outcome
por: Brouqui, Philippe, et al.
Publicado: (2021)

Reply to Lebeaux D, Revest M. No evidence of clinical benefits of early treatment of COVID-19 patients with hydroxychloroquine and azithromycin
por: Million, Matthieu, et al.
Publicado: (2021)

Outcomes of 3,737 COVID-19 patients treated with hydroxychloroquine/azithromycin and other regimens in Marseille, France: A retrospective analysis
por: Lagier, Jean-Christophe, et al.
Publicado: (2020)

Outcomes after early treatment with hydroxychloroquine and azithromycin: An analysis of a database of 30,423 COVID-19 patients
por: Brouqui, Philippe, et al.
Publicado: (2023)

Cardiovascular Safety of Hydroxychloroquine–Azithromycin in 424 COVID-19 Patients
por: Million, Matthieu, et al.
Publicado: (2023)

Clinical and microbiological effect of a combination of hydroxychloroquine and azithromycin in 80 COVID-19 patients with at least a six-day follow up: A pilot observational study
por: Gautret, Philippe, et al.
Publicado: (2020)

Re: ‘Effect of hydroxychloroquine with or without azithromycin on the mortality of COVID-19 patients’ by Fiolet et al.
por: Million, Matthieu, et al.
Publicado: (2021)

Response to the use of hydroxychloroquine in combination with azithromycin for patients with COVID-19 is not supported by recent literature.
por: Gautret, Philippe, et al.
Publicado: (2021)

Early treatment of COVID-19 patients with hydroxychloroquine and azithromycin: A retrospective analysis of 1061 cases in Marseille, France
por: Million, Matthieu, et al.
Publicado: (2020)

WITHDRAWN: Early combination therapy with hydroxychloroquine and azithromycin reduces mortality in 10,429 COVID-19 outpatients
por: Million, Matthieu, et al.
Publicado: (2021)

Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open label non-randomized clinical trial revisited
por: Gautret, Philippe, et al.
Publicado: (2021)

Effect of hydroxychloroquine and azithromycin on SARS-CoV-2 clearance in COVID-19 patients, a meta-analysis.
por: Million, Matthieu, et al.
Publicado: (2021)

Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open-label non-randomized clinical trial
por: Gautret, Philippe, et al.
Publicado: (2020)

Safety profile of hydroxychloroquine and azithromycin combined treatment in COVID-19 patients
por: Gautret, Philippe, et al.
Publicado: (2021)

Pro-apoptotic effect of doxycycline and hydroxychloroquine on B-cell lymphoma induced by C. burnetii
por: Melenotte, Cléa, et al.
Publicado: (2017)

Expression of ACE2, Soluble ACE2, Angiotensin I, Angiotensin II and Angiotensin-(1-7) Is Modulated in COVID-19 Patients
por: Osman, Ikram Omar, et al.
Publicado: (2021)

Effect of hydroxychloroquine and azithromycin on the viral clearance of SARS-CoV-2: response to Hervé Seligmann
por: Gautret, Philippe, et al.
Publicado: (2021)

Clinical efficacy and safety profile of hydroxychloroquine and azithromycin against COVID-19
por: Gautret, Philippe, et al.
Publicado: (2021)

Hydroxychloroquine + azithromycin treatment in elderly patients
por: Gautret, Philippe, et al.
Publicado: (2021)

Response to uncertain effect of hydroxychloroquine and azithromycin on SARS-CoV-2 viral load.
por: Gautret, Philippe, et al.
Publicado: (2021)

In vitro testing of combined hydroxychloroquine and azithromycin on SARS-CoV-2 shows synergistic effect
por: Andreani, Julien, et al.
Publicado: (2020)

Chloroquine and hydroxychloroquine as available weapons to fight COVID-19
por: Colson, Philippe, et al.
Publicado: (2020)

Rapid viral diagnosis and ambulatory management of suspected COVID-19 cases presenting at the infectious diseases referral hospital in Marseille, France, - January 31st to March 1st, 2020: A respiratory virus snapshot
por: Amrane, Sophie, et al.
Publicado: (2020)

Effect of hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open-label non-randomized clinical trial, an update with an intention-to-treat analysis and clinical outcomes
por: Gautret, Philippe, et al.
Publicado: (2021)

SARS-CoV-2 Vaccination and Protection Against Clinical Disease: A Retrospective Study, Bouches-du-Rhône District, Southern France, 2021
por: Fournier, Pierre-Edouard, et al.
Publicado: (2022)

Does spitting in public play a role in transmitting SARS-CoV-2?
por: Gautret, Philippe, et al.
Publicado: (2020)

Evaluating the serological status of COVID-19 patients using an indirect immunofluorescent assay, France
por: Edouard, S., et al.
Publicado: (2020)

Clinical outcomes in patients infected with different SARS-CoV-2 variants at one hospital during three phases of the COVID-19 epidemic in Marseille, France
por: Hoang, Van-Thuan, et al.
Publicado: (2021)

Children account for a small proportion of diagnoses of SARS-CoV-2 infection and do not exhibit greater viral loads than adults
por: Colson, Philippe, et al.
Publicado: (2020)

Evaluation of pain susceptibility by taking blood pressure in patients with infections: A prospective comparative study
por: Eldin, Carole, et al.
Publicado: (2021)

Interpretation of SARS-CoV-2 PCR results for the diagnosis of COVID-19
por: Colson, Philippe, et al.
Publicado: (2021)

Rickettsia mongolitimonae Encephalitis, Southern France, 2018
por: Loarte, María Dolores Corbacho, et al.
Publicado: (2020)

Automated Western immunoblotting detection of anti-SARS-CoV-2 serum antibodies
por: Edouard, Sophie, et al.
Publicado: (2021)

Long-Term Persistence of Olfactory and Gustatory Disorders in COVID-19 Patients
por: Nguyen, Nhu Ngoc, et al.
Publicado: (2022)

Prevalence and risk factors for lung involvement on low-dose chest CT (LDCT) in a paucisymptomatic population of 247 patients affected by COVID-19
por: Castelli, Maxime, et al.
Publicado: (2020)

Correction to: Prevalence and risk factors for lung involvement on low-dose chest CT (LDCT) in a paucisymptomatic population of 247 patients affected by COVID-19
por: Castelli, Maxime, et al.
Publicado: (2021)

SARS-CoV-2 quasi-species analysis from patients with persistent nasopharyngeal shedding
por: Dudouet, Pierre, et al.
Publicado: (2022)

Clinical Features and Complications of Coxiella burnetii Infections From the French National Reference Center for Q Fever
por: Melenotte, Cléa, et al.
Publicado: (2018)

The emergence, dynamics and significance of SARS-CoV-2 variants
por: COLSON, Philippe, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_dhn9ltm8sdlms6d87d4gacso5p